| Primary |
| Rheumatoid Arthritis |
80.0% |
| Ankylosing Spondylitis |
10.0% |
| Psoriasis |
10.0% |
|
| Urosepsis |
25.0% |
| Chronic Myeloid Leukaemia |
12.5% |
| Epstein-barr Virus Test Positive |
12.5% |
| Extradural Abscess |
12.5% |
| Hypertension |
12.5% |
| Suicide Attempt |
12.5% |
| Wound |
12.5% |
|
| Secondary |
| Rheumatoid Arthritis |
61.5% |
| Product Used For Unknown Indication |
15.4% |
| Intrauterine Infection |
5.1% |
| Osteoporosis |
5.1% |
| Polyarthritis |
5.1% |
| Catheter Related Infection |
2.6% |
| Dysuria |
2.6% |
| Osteoporosis Prophylaxis |
2.6% |
|
| Paraesthesia |
20.0% |
| Suicide Attempt |
13.3% |
| Tooth Infection |
13.3% |
| Depression |
6.7% |
| Gastric Ulcer |
6.7% |
| Mucosal Inflammation |
6.7% |
| Renal Failure Acute |
6.7% |
| Rheumatoid Arthritis |
6.7% |
| Small Cell Lung Cancer Stage Unspecified |
6.7% |
| Ulcerative Keratitis |
6.7% |
| Vomiting |
6.7% |
|
| Concomitant |
| Rheumatoid Arthritis |
64.6% |
| Psoriatic Arthropathy |
8.9% |
| Psoriasis |
5.3% |
| Drug Use For Unknown Indication |
3.0% |
| Product Used For Unknown Indication |
3.0% |
| Osteoporosis |
1.8% |
| Back Pain |
1.7% |
| Juvenile Arthritis |
1.6% |
| Osteoarthritis |
1.3% |
| Pain |
1.2% |
| Prophylaxis |
1.1% |
| Anxiety |
1.0% |
| Gastrooesophageal Reflux Disease |
1.0% |
| Ankylosing Spondylitis |
0.8% |
| Hypertension |
0.8% |
| Systemic Lupus Erythematosus |
0.8% |
| Fibromyalgia |
0.6% |
| Vitamin Supplementation |
0.6% |
| Anaemia |
0.5% |
| Haemoglobin Decreased |
0.5% |
|
| Rheumatoid Arthritis |
18.5% |
| Injection Site Pain |
16.5% |
| Injection Site Erythema |
7.5% |
| Drug Ineffective |
7.3% |
| Sinusitis |
5.3% |
| Arthralgia |
4.8% |
| Pain In Extremity |
4.8% |
| Injection Site Swelling |
4.2% |
| Pain |
4.0% |
| Nausea |
3.3% |
| Fatigue |
3.1% |
| Injection Site Haematoma |
3.1% |
| Headache |
2.4% |
| Joint Swelling |
2.4% |
| Oedema Peripheral |
2.4% |
| Psoriatic Arthropathy |
2.2% |
| Upper Respiratory Tract Infection |
2.2% |
| Diarrhoea |
2.0% |
| Injection Site Haemorrhage |
2.0% |
| Injection Site Pruritus |
2.0% |
|
